Showing results (71-80 of 90) with videos related to
Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiformeC Twelves, M Campone, B Coudert, et al.European Journal of Cancer (Oxford, England : 1990)|October 26, 2001
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group reportB Coudert, A Anthoney, W Fiedler, et al.Cerebrovascular Diseases (Basel, Switzerland)|April 24, 2010
Reliability of the ECASS radiological classification of postthrombolysis brain haemorrhage: a comparison of CT and three MRI sequencesP Renou, I Sibon, T Tourdias, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancerH Curé, V Chevalier, A Adenis, et al.The European Respiratory Journal|June 11, 2011
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3I Borget, J Cadranel, J-P Pignon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2001
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patientsY Bécouarn, E Gamelin, B Coudert, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2012
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysisS Giacchetti, P A Dugué, P F Innominato, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2010
Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapyS Guiu, M Liegard, L Favier, et al.Gynecologic Oncology|October 20, 1999
A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation studyC Lhommé, P Vennin, N Callet, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II studyJ-Y Douillard, R Gervais, G Dabouis, et al.Pageof 9